LAUSR

Canine inflammatory mammary cancer (IMC) has long been regarded as an attractive animal model for research into human inflammatory breast cancer (IBC), Although some canine mammary tumor cell lines corresponding to human mammary cancer cell lines have been established, there is still a need to supplement the canine mammary tumor cell bank. The goal of this study was to create a new type of IMC cell line. The primary tumor, IMC-118, was identified as IMC by pathology examination. Immunohistochemistry (IHC) analysis revealed negative immunoreactivity to estrogen receptor (ER), but positive immunoreactivity to progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2). Immunofluorescence (IF) analysis revealed that the IMC-118 cell line from this primary tumor was negative for ER but positive for PR and HER-2, and was also positive for epithelial and mesenchymal cell markers. This cell line was cultured stably for more than 50 passages and grew well after cryopreservation. In vivo, tumor masses and metastases in the lungs were discovered after inoculating the IMC-118 cells into the nude mice model. As a result, a novel canine inflammatory mammary cancer cell line, IMC-118, was effectively established, and could be employed as a promising model for immunotherapy and epithelial-mesenchymal transition (EMT) mechanism of inflammatory mammary cancer research in both dogs and humans. This article is protected by copyright. All rights reserved.